piritrexim has been researched along with epiroprim in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (50.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Queener, SF | 1 |
Gangjee, A; Queener, SF; Vasudevan, A | 1 |
Griffin, RJ; Grunwaldt, JD; Lambert, PA; Meek, MA; Queener, SF; Robson, C; Schmidt, D | 1 |
Forsch, RA; Queener, SF; Rosowsky, A | 1 |
Chan, DC; Fu, H; Queener, SF; Rosowsky, A | 1 |
Boesche, M; Crowther, GJ; Dasari, KS; Drewes, G; El Bakkouri, M; Fox, AM; Ghidelli-Disse, S; He, P; Hillesland, HK; Hui, R; Jones, JC; Keyloun, KR; Krahn, MM; Lafuente-Monasterio, MJ; Leonard, SE; Leroy, D; Maly, DJ; Mo, JS; Ojo, KK; Reid, MC; Rivas, KL; Van Voorhis, WC | 1 |
1 review(s) available for piritrexim and epiroprim
Article | Year |
---|---|
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
Topics: Animals; Drug Design; Humans; Immunosuppression Therapy; Molecular Structure; Opportunistic Infections; Pneumonia, Pneumocystis; Structure-Activity Relationship | 1995 |
5 other study(ies) available for piritrexim and epiroprim
Article | Year |
---|---|
Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases.
Topics: AIDS-Related Opportunistic Infections; Animals; Folic Acid Antagonists; Humans; Liver; Mice; Pneumocystis; Pyrimidines; Rats; Tetrahydrofolate Dehydrogenase; Toxoplasma; Trimetrexate | 1997 |
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Survival; Folic Acid Antagonists; Indicators and Reagents; Kinetics; Liver; Lymphoma, Large B-Cell, Diffuse; Mice; Pneumocystis; Pyrimidines; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 1997 |
Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity
Topics: Animals; Folic Acid Antagonists; Liver; Mycobacterium avium; Pneumocystis; Pyrimidines; Rats; Species Specificity; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Trimethoprim | 2002 |
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
Topics: Animals; Azepines; Benzazepines; Folic Acid Antagonists; Models, Molecular; Mycobacterium avium; Pneumocystis carinii; Pteridines; Rats; Solubility; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Water | 2004 |
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
Topics: Antimalarials; Calcium; Cell Line, Tumor; Hep G2 Cells; Humans; Malaria, Falciparum; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase Kinases; Plasmodium falciparum; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protozoan Proteins | 2016 |